New England Journal of Medicine· 2016Q1
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- 10,140citations
- Q1SCImago
- 2016year
Short summary
Pembrolizumab significantly improved progression-free survival (10.3 vs. 6.0 months) and overall survival (80.2% at 6 months vs. 72.4%) in patients with advanced non-small-cell lung cancer (NSCLC) expressing PD-L1 on at least 50% of tumor cells, compared to chemotherapy.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Oncology
OncologyMedicine